VZ:NYSEVerizon Communications Inc. Analysis
Data as of 2026-05-28 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Verizon’s stock is trading just above its 20‑day (≈ 47.5) and 50‑day (≈ 48.0) simple moving averages, with the price (≈ 48.2) also sitting above the 200‑day SMA (≈ 44.2), suggesting a modest bullish bias. The MACD histogram is positive and the signal line is negative, reinforcing the short‑term upside, while the RSI at 55 indicates the shares are not yet overbought. Valuation metrics are mixed: a forward P/E of ~9.1 and a trailing P/E of ~11.8 are well below the industry average of ~17, implying relative cheapness, yet the DCF‑derived fair value (~23.8) is far beneath the current market price, flagging potential overvaluation on a cash‑flow basis. The dividend yield remains attractive at nearly 5.9% with a payout ratio around 67%, and free cash flow exceeds $19 B, supporting dividend sustainability despite a high debt‑to‑equity ratio (~192) that warrants monitoring. Volatility over the past 30 days is about 22%, but beta is slightly negative (‑0.12), indicating limited market‑direction risk; support sits near $45.8 and resistance near $49.0, framing a tight trading range. Overall, the stock offers a solid income profile and value‑oriented pricing, but the heavy leverage and divergent DCF estimate temper enthusiasm.
Market Outlook
Short Term
< 1 yearKey Factors
- Price hovering near resistance at $49.0
- Bullish MACD but neutral overall trend
- Stable volume and low beta limiting short‑term volatility
Medium Term
1–3 yearsKey Factors
- Attractive dividend yield and coverage by free cash flow
- P/E multiples well below industry peers
- Analyst consensus (22 analysts) leaning toward a buy with a median target of $50.5
Long Term
> 3 yearsKey Factors
- Strong cash‑flow generation supporting dividend sustainability
- Long‑term demand for wireless and fiber services
- High leverage requires monitoring but is offset by consistent earnings
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.